|
|
- 2018
抗苗勒氏管激素在妇科肿瘤领域的应用前景
|
Abstract:
| [1] | Salihoglu KN, Dilbaz B, Cirik DA, et al. Short-term impact of laparoscopic cystectomy on ovarian reserve tests in bilateral and unilateral endometriotic and nonendometriotic cysts[J]. J Minim Invasive Gynecol, 2016, 23(5): 719-725. |
| [2] | Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3): 370-385. |
| [3] | Rey RA, Lhomme C, Marcillac I, et al. Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol[J]. Am J Obstet Gynecol, 1996, 174(3): 958-965. |
| [4] | Haltia UM, Hallamaa M, Tapper J, et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors[J]. Gynecol Oncol, 2017, 144(1): 83-89. |
| [5] | Sahin C, Taylan E, Akdemir A, et al. The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 205: 150-152. |
| [6] | Vignali M, Mabrouk M, Ciocca E, et al. Surgical excision of ovarian endometriomas: does it truly impair ovarian reserve? Long term anti-Mullerian hormone(AMH)changes after surgery[J]. J Obstet Gynaecol Res, 2015, 41(11): 1773-1778. |
| [7] | Ferrero S, Venturini PL, Gillott DJ, et al. Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial[J]. J Minim Invasive Gynecol, 2012, 19(6): 722-730. |
| [8] | Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort[J]. Lancet Oncol, 2013, 14(9): 873-881. |
| [9] | Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound[J]. Hum Reprod, 2003, 18(11): 2368-2374. |
| [10] | Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Mullerian hormone evaluation in gynecological endocrinology[J]. Hormones(Athens), 2011, 10(2): 95-103. |
| [11] | McLucas B, Voorhees WD 3rd, Snyder SA. Anti-Mullerian hormone levels before and after uterine artery embolization[J]. Minim Invasive Ther Allied Technol, 2018, 27(3):186-190. |
| [12] | Wang HY, Quan S, Zhang RL, et al. Comparison of serum anti-Mullerian hormone levels following hysterectomy and myomectomy for benign gynaecological conditions[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 171(2): 368-371. |
| [13] | Yuan H, Wang C, Wang D, et al. Comparing the effect of laparoscopic supracervical and total hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-mullerian hormone levels: a prospective cohort study[J]. J Minim Invasive Gynecol, 2015, 22(4): 637-641. |
| [14] | Song T, Kim MK, Kim ML, et al. Impact of opportunistic salpingectomy on anti-Mullerian hormone in patients undergoing laparoscopic hysterectomy: a multicentre randomised controlled trial[J]. BJOG, 2017, 124(2): 314-320. |
| [15] | Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study[J]. J Clin Oncol, 2006, 24(7): 1045-1051. |
| [16] | Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer[J]. Hum Reprod, 2006, 21(10): 2583-2592. |
| [17] | Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis[J]. Obstet Gynecol, 2015, 126(1): 187-195. |
| [18] | Muraji M, Sudo T, Iwasaki S, et al. The effect of abdominal radical trachelectomy on ovarian reserve: serial changes in serum anti-mullerian hormone levels[J]. J Cancer, 2012, 3: 191-195. |
| [19] | Farkkila A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumors—a comparative study with inhibin B[J]. Int J Cancer, 2015, 137(7): 1661-1671. |
| [20] | Giampaolino P, Bifulco G, Di Spiezio Sardo A, et al. Endometrioma size is a relevant factor in selection of the most appropriate surgical technique: a prospective randomized preliminary study[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 195: 88-93. |
| [21] | Green DM, Nolan VG, Kawashima T, et al. Decreased fertility among female childhood cancer survivors who received 22-27 Gy hypothalamic/pituitary irradiation: a report from the Childhood Cancer Survivor Study[J]. Fertil Steril, 2011, 95(6): 1922-1927. |
| [22] | Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary?[J]. Hum Reprod Update, 2012, 18(5): 525-535. |
| [23] | Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy[J]. Fertil Steril, 2013, 99(2): 477-483. |
| [24] | Decanter C, Morschhauser F, Pigny P, et al. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results[J]. Reprod Biomed Online, 2010, 20(2): 280-285. |
| [25] | Bi X, Zhang J, Cao D, et al. Anti-Mullerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study[J]. Oncotarget, 2017, 8(69): 113920-113927. |
| [26] | Rosendahl M, Andersen CY, la Cour Freiesleben N, et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age[J]. Fertil Steril, 2010, 94(1): 156-166. |
| [27] | Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer[J]. J Clin Endocrinol Metab, 2011, 96(5): 1336-1343. |
| [28] | Naasan M, Harrity C, Rajab H, et al. Patients with cancer at the margins of reproductive age had reduced levels of anti-Mullerian hormone compared with patients experiencing infertility[J]. Int J Gynaecol Obstet, 2016, 133(2): 226-229. |
| [29] | Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer[J]. Eur J Cancer, 2013, 49(16): 3404-3411. |
| [30] | Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells[J]. Cell, 1986, 45(5): 685-698. |
| [31] | Kelsey TW, Anderson RA, Wright P, et al. Data-driven assessment of the human ovarian reserve[J]. Mol Hum Reprod, 2012, 18(2): 79-87. |
| [32] | Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J]. Mol Hum Reprod, 2013, 19(8): 519-527. |
| [33] | Lindhardt JM, Hagen CP, Johannsen TH, et al. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development[J]. Int J Endocrinol, 2013, 2013:198698. |
| [34] | Huang H, Wang C, Tian Q. Gonadal tumour risk in 292 phenotypic female patients with disorders of sex development containing Y chromosome or Y-derived sequence[J]. Clin Endocrinol(Oxf), 2017, 86(4): 621-627. |
| [35] | Moorman PG, Myers ER, Schildkraut JM, et al. Effect of hysterectomy with ovarian preservation on ovarian function[J]. Obstet Gynecol, 2011, 118(6): 1271-1279. |
| [36] | Trabuco EC, Moorman PG, Algeciras-Schimnich A, et al. Association of ovary-sparing hysterectomy with ovarian reserve[J]. Obstet Gynecol, 2016, 127(5): 819-827. |
| [37] | Asgari Z, Rouholamin S, Hosseini R, et al. Comparing ovarian reserve after laparoscopic excision of endometriotic cysts and hemostasis achieved either by bipolar coagulation or suturing: a randomized clinical trial[J]. Arch Gynecol Obstet, 2016, 293(5): 1015-1022. |
